Voyager Therapeutics (VYGR) Cash from Financing Activities (2014 - 2026)
Voyager Therapeutics (VYGR) posted Cash from Financing Activities of $3.3 million for Q1 2026, up 2350.0% sequentially from $136000.0 in Q4 2025, and up 3963.41% YoY from $82000.0 in Q1 2025.
Voyager Therapeutics (VYGR) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 3963.41% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 227.64% YoY) and the FY2025 annual result came in at $816000.0, down 99.28% from the prior year.
- Cash from Financing Activities grew to $3.3 million in Q1 2026 per VYGR's latest filing, from $136000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $112.9 million in Q1 2024 and troughed at $12000.0 in Q1 2022.
- A 5-year average of $9.0 million and a median of $460000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 260783.33% in 2023, then tumbled 99.93% in 2025.
- Over 5 years, Cash from Financing Activities stood at $276000.0 in 2022, then soared by 66.67% to $460000.0 in 2023, then grew by 24.78% to $574000.0 in 2024, then plunged by 76.31% to $136000.0 in 2025, then soared by 2350.0% to $3.3 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.3 million, $136000.0, and $85000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - | 2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.91 Mn |
| Jun 30, 2026 | 2.91 Mn |
| Mar 31, 2026 | 3.33 Mn |
| Mar 31, 2026 | 3.33 Mn |
| Dec 31, 2025 | 136,000.00 |
| Dec 31, 2025 | 136,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 513,000.00 |
| Jun 30, 2025 | 513,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 574,000.00 |
| Dec 31, 2024 | 574,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Mar 31, 2024 | 112.86 Mn |
| Mar 31, 2024 | 112.86 Mn |